ANI Pharmaceuticals, Inc.
HealthcareNASDAQ:ANIP · NASDAQ Global Market
+$0.03 today
Vol 0.18M · Avg 0.37M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
14.5%
avg -0.1%
ROIC
5.6%
avg 2.0%
ROA
5.4%
avg 0.1%
Analysis
ROE is currently the strongest return metric at 14.5% versus its period average of -0.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Nikhil Lalwani | President, Chief Executive Officer & Director | $2.43M | — | 48 | $349,889.00 | 1.54% |
Christopher K. Mutz | Senior Vice President & Head of Rare Disease | $1.27M | — | 54 | $91,309.00 | 0.40% |
Stephen Carey | Senior Vice President of Finance & Chief Financial Officer | $1.12M | — | 55 | $6,626.00 | 0.03% |
Ori Gutwerg | Senior Vice President of Generics | $964,148.00 | — | 51 | $78,696.00 | 0.35% |
Meredith W. Cook | Senior Vice President, General Counsel & Corporate Secretary | $860,808.00 | — | 52 | $78,390.00 | 0.34% |
Chad Gassert | Senior Vice President of Corporate Development & Strategy | $849,711.00 | — | 50 | $74,916.00 | 0.33% |
Mary Pao | Chief Medical Officer | — | — | — | — | — |
Thomas Andrew Rowland | Senior Vice President & Head of Established Brands | — | — | 59 | $38,878.00 | 0.17% |
Elizabeth Powell | Chief Compliance Officer & Head of Legal of Rare Disease | — | — | — | — | — |
Krista L. Davis | Senior Vice President & Chief Human Resources Officer | — | — | 53 | $51,946.00 | 0.23% |
Muthusamy Shanmugam | Head of R&D, Chief Operating Officer of New Jersey Operations & Director | — | — | 58 | $101,056.00 | 0.44% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
58
$49.17M
Net Sentiment
$49.17M
Net selling
Most Active
Cook Meredith
12 transactions
1–10 of 58
Analysis
Insiders reported 0 buys worth $0.00 and 58 sells worth $49.17M over the last 12 months. That adds up to net selling of $49.17M. Cook Meredith was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +17.7% (15yr)2 analysts |
| Revenue | N/A | N/A | +221.3% | +22.3% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | +22.5% (15yr)2 analysts |
| EBIT | N/A | N/A | N/A | +21.8% (15yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +221.3% over three years. Forward estimates point to Net Income at +22.5% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Trulieve Cannabis Corp.
TCNNF
$2.22B
Hisamitsu Pharmaceutical Co., Inc.
HTSUF
$2.04B
Dermapharm Holding SE
DMPHF
$1.96B
Fagron N.V.
ARSUF
$1.95B
Green Thumb Industries Inc.
GTBIF
$1.85B
Tsumura & Co.
TSMRF
$1.73B
Harrow Health, Inc.
NASDAQ:HROW
$1.40B
CanSino Biologics Inc.
CASBF
$1.08B
Tilray Brands, Inc.
NASDAQ:TLRY
$595.63M
BGM Group Ltd.
NASDAQ:BGM
$75.23M
Who manages ANIP?
ANI Pharmaceuticals, Inc. (ANIP) lists 11 active executives. The top listed executive is Nikhil Lalwani, President, Chief Executive Officer & Director.
Are ANIP insiders buying or selling?
Recent insider activity shows net selling of $60.46M.
Explore More
Continue the stock analysis
Jump to another research area for this company.